中国药物应用与监测
中國藥物應用與鑑測
중국약물응용여감측
CHINESE JOURNAL OF DRUG APPLICATION AND MONITORING
2015年
2期
69-72
,共4页
郭磊%李爱洁%王键玮%陶海涛%胡毅
郭磊%李愛潔%王鍵瑋%陶海濤%鬍毅
곽뢰%리애길%왕건위%도해도%호의
埃克替尼%肺腺癌%回顾性研究
埃剋替尼%肺腺癌%迴顧性研究
애극체니%폐선암%회고성연구
Icotinib%Lung adenocarcinoma%Retrospective study
目的：探讨盐酸埃克替尼治疗晚期肺腺癌的有效性和安全性。方法：利用我院肿瘤患者数据库，回顾性筛选2012年1月–2014年1月于本中心接受盐酸埃克替尼治疗的晚期肺腺癌患者，对符合纳入标准的患者采集年龄、性别、PS评分、肿瘤分期、分子病理改变、用药情况、不良反应等相关临床资料，并对患者进行生存随访。结果：本研究共纳入42例患者，共27例患者接受了EGFR突变基因检测，其中EGFR突变阳性21例。近期疗效方面，RR为38.1%（16/42）；DCR为73.8%（31/42）。中位随访时间为15个月，全组人群中位PFS为14.5个月（95％CI：12.4–16.6个月）。单因素分析显示PFS与年龄、PS评分、治疗前CEA水平、是否放疗、是否脑转移无关（P >0.05），而与性别、吸烟状况、EGFR基因突变状况有关。常见的不良反应为皮疹和恶心呕吐，大部分为Ⅰ~Ⅱ度。结论：盐酸埃克替尼治疗晚期肺腺癌临床效果显著，耐受性好，可作为EGFR敏感突变的新选择。
目的：探討鹽痠埃剋替尼治療晚期肺腺癌的有效性和安全性。方法：利用我院腫瘤患者數據庫，迴顧性篩選2012年1月–2014年1月于本中心接受鹽痠埃剋替尼治療的晚期肺腺癌患者，對符閤納入標準的患者採集年齡、性彆、PS評分、腫瘤分期、分子病理改變、用藥情況、不良反應等相關臨床資料，併對患者進行生存隨訪。結果：本研究共納入42例患者，共27例患者接受瞭EGFR突變基因檢測，其中EGFR突變暘性21例。近期療效方麵，RR為38.1%（16/42）；DCR為73.8%（31/42）。中位隨訪時間為15箇月，全組人群中位PFS為14.5箇月（95％CI：12.4–16.6箇月）。單因素分析顯示PFS與年齡、PS評分、治療前CEA水平、是否放療、是否腦轉移無關（P >0.05），而與性彆、吸煙狀況、EGFR基因突變狀況有關。常見的不良反應為皮疹和噁心嘔吐，大部分為Ⅰ~Ⅱ度。結論：鹽痠埃剋替尼治療晚期肺腺癌臨床效果顯著，耐受性好，可作為EGFR敏感突變的新選擇。
목적：탐토염산애극체니치료만기폐선암적유효성화안전성。방법：이용아원종류환자수거고，회고성사선2012년1월–2014년1월우본중심접수염산애극체니치료적만기폐선암환자，대부합납입표준적환자채집년령、성별、PS평분、종류분기、분자병리개변、용약정황、불량반응등상관림상자료，병대환자진행생존수방。결과：본연구공납입42례환자，공27례환자접수료EGFR돌변기인검측，기중EGFR돌변양성21례。근기료효방면，RR위38.1%（16/42）；DCR위73.8%（31/42）。중위수방시간위15개월，전조인군중위PFS위14.5개월（95％CI：12.4–16.6개월）。단인소분석현시PFS여년령、PS평분、치료전CEA수평、시부방료、시부뇌전이무관（P >0.05），이여성별、흡연상황、EGFR기인돌변상황유관。상견적불량반응위피진화악심구토，대부분위Ⅰ~Ⅱ도。결론：염산애극체니치료만기폐선암림상효과현저，내수성호，가작위EGFR민감돌변적신선택。
Objective: To evaluate the efficacy and safety of icotinib in patients with advanced non-small cell lung adenocarcinoma. Methods: A total of 42 patients with advanced non-small cell lung adenocarcinoma treated by icotinib from January 2012 to January 2014 in our hospital were collected. The information of the patients that met the included standards in respect of age, gender, PS score, tumor stage, pathological changes, medication, toxicities and so on were collected. Results:Among the 42 patients, 27 patients underwent EGFR mutation detection, and 21 cases were found EGFR mutation. The recent curative effect of RR was 38.1%(16/42) and DCR was 73.8%(31/42). The median follow-up time was iffteen months. The PFS of the whole group was 14.5 months (95%CI:12.4–16.6 months). The univariate analysis showed that FPS was more correlated with gender, smoking index, EGFR mutation, rather than age, PS score, CEA levels before treatment, whether radiotherapy and brain metastases or not (P > 0.05). The main toxicities of icotinib were rash, nausea and vomiting which do not need further treatment. Conclusion: The efficacy of icotinib for the treatment of advanced non-small cell lung adenocarcinoma is noble in longer PFS, with better disease control rates and less toxicity. Icotinib could be used as a new choice for the patients with EGFR mutation.
